Reddit Leaps on Q2 Sales
Reddit (NYSE:RDDT) shares sprang to life early Friday after the company reported second-quarter earnings on Thursday that beat on sales and guidance.Earnings per share were 45 cents vs. 19 cents expected. Revenue proved to be $500 million vs. $426 million expectedReddit’s revenue grew 78% year-over-year in the second quarter and was 17% above consensus estimates, the biggest beat in its short history as a public company. Net income came in at $89 million in the second quarter, compared with a net loss of $10 million in the second quarter of last year due to costs associated with its IPO.The company said third-quarter revenue will be in the range of $535 million to $545 million, ahead of Wall Street estimates of $473 million.Adjusted earnings in the third quarter are projected to be in between $185 million to $195 million, ahead of estimates of $160 million.Reddit said global daily active users for the quarter grew 21% year-over-year to 110.4 million, ahead of analyst estimates of 109 million.The company said second-quarter global average revenue per user was $4.53, topping analyst estimates of $3.90.Reddit’s second-quarter sales in the U.S. were $409 million, ahead of estimates of $335 million. International revenue was $91 million in the quarter, compared with $89 million that experts projected.RDDT shares jumped $24.22, or 15.1%, to $184.81.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


